Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 13/20 | 0.62 |
| ▸ | LTB4R2 | Q9NPC1 | 9/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476 | 1.00 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL14971365 | 1.00 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL6460181 | 0.95 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL30929318 | 0.93 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2156925 | 0.93 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL2542 | 0.93 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL1560689 | 0.93 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21408288 | 0.93 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL157179 | 0.93 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL29406387 | 0.93 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886767-A | Synthesis method of N-methyl substituted valsartan impurity | 珠海润都制药股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-102822151-B | Improved process for the preparation of valsartan | KRKA D D NOVO MESTO | 2015-03-18 | — | — | CN | claimed |
| EP-2556059-B1 | IMPROVED PROCESS FOR PREPARING VALSARTAN | KRKA D D NOVO MESTO (SI) | 2014-05-07 | — | — | EP | claimed |
| EP-2556059-A1 | IMPROVED PROCESS FOR PREPARING VALSARTAN | KRKA, d.d., Novo mesto (SI) | 2013-02-13 | — | — | EP | claimed |
| CN-102822151-A | Improved process for the preparation of valsartan | KRKA D D NOVO MESTO | 2012-12-12 | — | — | CN | claimed |
| WO-2011124655-A1 | IMPROVED PROCESS FOR PREPARING VALSARTAN | KRKA, D.D., NOVO MESTO (SI) | 2011-10-13 | — | — | WO | claimed |
| CN-102822151-B | Improved process for the preparation of valsartan | KRKA D D NOVO MESTO | 2015-03-18 | — | — | CN | disclosed |
| EP-2556059-B1 | IMPROVED PROCESS FOR PREPARING VALSARTAN | KRKA D D NOVO MESTO (SI) | 2014-05-07 | — | — | EP | disclosed |
| EP-2556059-A1 | IMPROVED PROCESS FOR PREPARING VALSARTAN | KRKA, d.d., Novo mesto (SI) | 2013-02-13 | — | — | EP | disclosed |
| CN-102822151-A | Improved process for the preparation of valsartan | KRKA D D NOVO MESTO | 2012-12-12 | — | — | CN | disclosed |
| WO-2011124655-A1 | IMPROVED PROCESS FOR PREPARING VALSARTAN | KRKA, D.D., NOVO MESTO (SI) | 2011-10-13 | — | — | WO | disclosed |
| US-20080275096-A1 | Process for the preparation of valsartan | HAREL ZVI | 2008-11-06 | — | — | US | disclosed |
| US-20080275096-A1 | Process for the preparation of valsartan | HAREL ZVI | 2008-11-06 | — | — | US | disclosed |
| US-7378531-B2 | Process for the preparation of valsartan | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2008-05-27 | — | — | US | disclosed |
| US-7378531-B2 | Process for the preparation of valsartan | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2008-05-27 | — | — | US | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275096-A1 | Process for the preparation of valsartan | REN, AGT, AVPR2 | AGTR1 13/4885LTB4R2 3075/4885ABCB11 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.